DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Insights into the Molecular Mechanisms of Genetic Predisposition to Hematopoietic Malignancies: The Importance of Gene–Environment Interactions
The recognition of host genetic factors underlying susceptibility to hematopoietic malignancies has
increased greatly over the last decade. Historically, germline predisposition was thought to primarily affect the
young. However, emerging data indicate that hematopoietic malignancies that develop in people of all ages across
the human lifespan can derive from germline predisposing conditions and are not exclusively observed in younger
individuals. The age at which hematopoietic malignancies manifest appears to correlate with distinct underlying biological pathways. Progression from having a deleterious germline variant to being diagnosed with overt malignancy
involves complex, multistep gene–environment interactions with key external triggers, such as infection and inflammatory stimuli, driving clonal progression. Understanding the mechanisms by which predisposed clones transform
under specific pressures may reveal strategies to better treat and even prevent hematopoietic malignancies from
occurring. Recent unbiased genome-wide sequencing studies of children and adults with hematopoietic malignancies have revealed novel genes in which disease-causing variants are of germline origin. This paradigm shift is spearheaded by findings in myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) as well as acute lymphoblastic
leukemia, but it also encompasses other cancer types. Although not without challenges, the field of genetic cancer
predisposition is advancing quickly, and a better understanding of the genetic basis of hematopoietic malignancies
risk affects therapeutic decisions as well as genetic counseling and testing of at-risk family members., Research at C. Cobaleda's laboratory was partially supported by Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021–122787OB-I00) and a Research Contract with the “Fundación Síndrome de Wolf-Hirschhorn o 4p-.” Institutional grants from the “Fundación Ramón Areces” and “Banco de Santander” to the CBMSO are also acknowledged. L.A. Godley receives funding from NIH/NCI U24CA258118, Edward P. Evans Foundation, NIH/HLHBI via Oregon Health & Science University R01HL155426, Leukemia & Lymphoma Society, NIH/NCI U01CA257666, and RUNX1 Research Program. K. Nichols receives funding from the American Lebanese Syrian Associated Charities (ALSAC), R01CA241452 from the NCI, R21AI113490 from the National Institute of Allergy and Infectious Diseases, Histiocytosis Association, and Cures within Reach. M.W. Wlodarski receives funding from ALSAC, Edward P. Evans Foundation, and The Vera and Joseph Dresner Foundation. Research in ISG group is partially supported by FEDER and by SAF2015–64420-R MINECO/FEDER, UE; by RTI2018–093314-B-I00 MCIU/AEI/FEDER, UE; by PID2021–122185OB-I00 MCIU/AEI/FEDER, UE; by Junta de Castilla y León (UIC-017, CSI001U16, CSI234P18, CSI144P20, and CSI016P23); and by the Fundacion Unoentrecienmil (CUNINA project). C. Cobaleda and I. Sánchez-García have been supported by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC)., Peer reviewed